Alto Neuroscience, Inc. ANRO
At closeNov 10, 2026, 4:01 PM EST
After hours · Nov 10, 4:01 PM ET
- YTD
- +60.73%
- 1 year
- +124.57%
- Market cap
- 1.12B
- EPS (ttm)
- -2.31
- Shares out
- 39.24M
- Forward P/E
- -8.55
- YTD return
- +60.73%
- 1-year return
- +124.57%
- Volume
- 515.79K
- Avg volume
- 577.46K
- Open
- 27.55
- Previous close
- 27.80
- Day's range
- 27.05 – 28.84
- 52-week range
- 10.80 – 37.48
- Beta
- 1.45
- Price target
- 38.67 (+35.2%)
- Earnings date
- Nov 11, 2026
Key statistics
- Enterprise value
- 870.49M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 4.58
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -42.90M
- Total cash
- 243.73M
- Total debt
- 23.29M
- Return on equity
- -49.17%
- Short % of float
- 15.54%
- 50-day average
- 26.84
- 200-day average
- 24.46
Analyst view
- Target (low)
- 26.00
- Target (mean)
- 38.67
- Target (high)
- 60.00
- Strong buy0
- Buy10
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate -0.72167.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | -0.67274 | — | — | — |
| Aug 12, 2026 | Jun 30, 2026 | -0.73454 | -0.65 | +0.08 | +11.51% |
| May 13, 2026 | Mar 31, 2026 | -0.56 | -0.80 | -0.24 | -42.86% |
| Mar 16, 2026 | Dec 31, 2025 | -0.56 | -0.45 | +0.11 | +19.64% |
| Nov 12, 2025 | Sep 30, 2025 | -0.66 | -0.52 | +0.14 | +21.21% |
| Aug 13, 2025 | Jun 30, 2025 | -0.57 | -0.65 | -0.08 | -14.04% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 17, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 13, 2026 | Wedbush | main | Neutral | Neutral |
| Aug 13, 2026 | BTIG | main | Buy | Buy |
| May 18, 2026 | Baird | main | Outperform | Outperform |
| May 14, 2026 | Wedbush | main | Neutral | Neutral |
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- altoneuroscience.com
News
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 
HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $60 
Alto Neuroscience Promotes Nick Smith To President, CFO, Effective Aug. 26 
HC Wainwright & Co. Maintains Buy on Alto Neuroscience, Raises Price Target to $55 
Wedbush Maintains Neutral on Alto Neuroscience, Raises Price Target to $26 
BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $37 - Alto Neuroscience Q2 EPS $(0.65) Beats $(0.73) Estimate
Alto Neuroscience Prices ~$100M Offering Of 3.776M Common Shares At $26.48/Share - Alto Neuroscience Intends To Accelerate And Expand Clinical Development Of ALTO-207, Including An Additional Planned Phase 3 Trial As Monotherapy For Treatment-Resistant Depression
Alto Neuroscience Publishes Trial Of Dopamine Agonist Pramipexole With Mood Disorders And Clinically Significant Anhedonia In Nature Medice
Your note
Sign in to keep a note on ANRO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ETKIN AMIT | Chief Executive Officer | Stock Gift | May 13, 2026 | 833,949 |
| SMITH NICHOLAS CONRAD | President | Conversion of Exercise of derivative security | Oct 1, 2026 | 79,060 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Alpha Wave Global, LP | 9.45% | 3,707,757 | 106.03M | Jun 29, 2026 |
| Commodore Capital Lp | 6.94% | 2,723,196 | 77.88M | Jun 29, 2026 |
| Blackrock Inc. | 5.40% | 2,121,009 | 60.66M | Jun 29, 2026 |
| Perceptive Advisors Llc | 4.10% | 1,609,893 | 46.04M | Jun 29, 2026 |
| Adage Capital Partners GP L.L.C. | 4.08% | 1,600,000 | 45.76M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.54% | 1,389,477 | 39.74M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.58% | 1,011,881 | 28.94M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.13% | 836,522 | 23.92M | Sep 29, 2026 |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 0.89% | 347,904 | 9.95M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.88% | 346,618 | 9.91M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.76% | 298,273 | 8.53M | Sep 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 0.73% | 287,033 | 8.21M | Aug 30, 2026 |